Aurinia Pharmaceuticals AUPH Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Kiniksa Pharmaceuticals International, plcKNSA

——

Alumis Inc.ALMS

——

Arrowhead ResearchARWR

——

BridgeBio PharmaBBIO

——

Ionis PharmaceuticalsIONS

——

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.39B+78.5%

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Aurinia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's contract liabilities, non-current?: Aurinia Pharmaceuticals (AUPH) reported contract liabilities, non-current of $12.65M in Q4 2025.